Pulmonary Arterial Hypertension (PAH) research hub
13 indexed studies · 9 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
This study looks at an inhaled medicine called GB002 for adults with pulmonary arterial hypertension (PAH). PAH causes high blood pressure in the lungs. Researchers want to see if taking this medicine over a longer time is safe and helps people walk further without getting out of breath.
Spain · Germany · Czechia - recruitingTherapeutic confirmatory (Phase III)
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
This study looks at a medicine called sotatercept for adults with pulmonary arterial hypertension (PAH). Researchers want to see how safe it is over a longer period when taken alongside usual treatments. It also checks whether the medicine helps improve walking ability, heart health, and everyday energy levels.
Poland · Belgium · Sweden - authorisedTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-controlled, Safety and Efficacy Study of VI-0106 (Extended-release Tacrolimus) in Subjects with PAH and Functional Limitations Despite Optimized Therapy with Available PAH Medications
This study tests whether a medicine called VI-0106 can help people with pulmonary arterial hypertension (PAH). PAH is high blood pressure in the lungs. Researchers want to see if adding this tablet to existing treatments helps people walk further and lowers the chance of their condition getting worse.
Italy · France · Czechia - authorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)
This study tests a new oral medicine called NS-863 for adults with pulmonary arterial hypertension (PAH). Researchers want to see if different doses can safely lower blood pressure in the lungs and improve daily symptoms and walking ability compared to a dummy tablet (placebo) over 24 weeks.
France · Germany · Poland - recruitingTherapeutic confirmatory (Phase III)
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (ADVANCE Outcomes)
This study is looking at a new medicine called Ralinepag for a lung condition called pulmonary arterial hypertension (PAH). It wants to see if Ralinepag can help patients feel better and prevent their condition from getting worse over time.
Hungary · Belgium · France - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo_Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality
This study is testing a new medicine, sotatercept, for adults with severe pulmonary arterial hypertension (PAH). Researchers want to see if adding sotatercept to existing treatments can prolong life, prevent lung transplants, or reduce hospital stays related to PAH worsening.
Belgium · Netherlands · Germany - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
This study is looking at a new medicine called sotatercept for people with pulmonary arterial hypertension (PAH). Researchers want to see how the body handles the medicine and check for any side effects. It’s a randomised study, meaning some people will get different doses.
Czechia · Poland · Spain - authorisedTherapeutic confirmatory (Phase III)
68Ga-FAPI PET/CT imaging to assess pulmonary artery and right ventricle remodeling SoFAPI study
This study uses a special scan called a PET/CT with a medicine called 68Ga-FAPI to look at the blood vessels in the lungs and the right side of the heart in people with a lung condition called Pulmonary Hypertension. We want to see how these parts change during treatment.
France - recruitingPhase II and Phase III (Integrated)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
This study is looking into a new treatment, AV-101, for Pulmonary Arterial Hypertension (PAH), a condition affecting the lungs and heart. It aims to see if the treatment is safe and effective by comparing it to a dummy medicine.
Czechia · Ireland · Poland - recruitingTherapeutic confirmatory (Phase III)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
This study looks at the long-term safety of a new medicine, AV-101, for people with pulmonary arterial hypertension (PAH). It's for those who have already tried AV-101 in a previous study and aims to learn more about how well it's tolerated over time.
Portugal · Italy · Sweden - completedPhase IV
Evaluating the accuracy of remote monitoring technology in capturing how patients respond to treatments for pulmonary arterial hypertension
This study is using small, implanted devices to check how well new and existing lung treatments work for people with Pulmonary Arterial Hypertension (PAH) from their own homes. It aims to help doctors find the best treatments faster and reduce hospital visits.
United Kingdom · England · Scotland - recruiting
COMPERA / COMPERA-KIDS
The COMPERA study is a registry helping doctors understand and improve treatment for an incurable lung condition called pulmonary hypertension (PH), including in children. It collects information on how existing treatments work in real life, to help everyone get the best care.
Belgium · Germany · Italy - recruitingPHASE2
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is looking at a new experimental drug, REGN13335, for adults with Pulmonary Arterial Hypertension (PAH). Researchers want to see if it's safe and effective when taken with other PAH medicines.
United States · Australia · Belgium